INSIGHTS
-
Get a Second Opinion Launches America’s First Pre‑Prescription Intelligence Platform
Get a Second Opinion today announced the nationwide debut of Pre‑Prescription Intelligence, a real‑time medication decision system that gives every patient clear visibility into efficacy, safety, interactions, and cost before a prescription is written. The platform delivers personalized guidance without requiring any personally identifiable information (PII), making it the first national‑scale medication intelligence system built…
-
New Cholesterol Guidelines Mean 87.5 Million U.S. Adults Are Now Eligible for Statins
Statins have been around for decades, but the number of people who qualify for them has just jumped in a major way. Updated cholesterol guidelines now classify 87.5 million U.S. adults as eligible for statin therapy. That is nearly one out of every three adults in the country. The change comes from new recommendations that…
-
Ensitrelvir Shows a Major Breakthrough in COVID-19 Prevention
As COVID-19 continues to evolve, one of the biggest challenges has been stopping the virus from spreading inside homes. When one person gets sick, the rest of the household is often at high risk. For years, there were vaccines to reduce severe illness, but there were no oral medications proven to prevent infection after exposure.…
-
Cyclospora Outbreak Surges Nationwide
Cyclospora infections have been rising sharply across the United States, and by July 20 the numbers showed a clear pattern: a major nationwide surge combined with a large, well-defined outbreak linked to iceberg lettuce. Together, these two streams of data paint a picture of a parasite that is spreading more widely than usual and causing…
-
FDA Approves First Generics of Gilotrif (afatinib) Tablets – What This Means for Patients
The FDA has officially approved the first generic versions of Gilotrif (afatinib) tablets, a targeted lung cancer treatment used for specific types of non-small cell lung cancer (NSCLC). This update matters because generics typically lower costs, expand access, and give patients more treatment options. The approval covers the same uses as the brand-name drug, meaning…
-
A Major Step Toward an HIV Vaccine: A Turning Point in the Fight Against HIV
For more than forty years, scientists have been trying to develop a vaccine that can protect people from HIV. The virus mutates quickly, hides behind sugar molecules, and evades the immune system in ways that make traditional vaccine approaches ineffective. But on July 9, 2026, researchers announced a breakthrough that could finally change the trajectory…
-
The Measles Surge of 2026: Why July Marked a Turning Point for the United States
Measles was once considered eliminated in the United States, but the events of 2026 made it clear that the virus has regained a foothold. By early July, public health officials were sounding alarms as case numbers climbed at a pace not seen in decades. The update released around July 6 was especially significant because it…
-
A Breakthrough in Early Autism Detection: How a Simple Nanosensor Could Change Diagnosis Forever
Autism has always been one of the most challenging conditions to diagnose early. Parents often wait years for clarity, navigating long evaluation processes and inconsistent screening tools. But a new study published in June 2026 introduced something genuinely groundbreaking: a nanosensor that can detect autism using a simple biochemical signal inside patient-derived stem cells. It…
-
Protein Powders and Shakes Contain High Levels of Lead: What Consumer Reports Found and What You Should Know
Protein powders and ready-to-drink shakes have become part of everyday life for millions of people. They’re in gym bags, office drawers, kitchen cabinets, and even school backpacks. Many people use them to build muscle, lose weight, recover from workouts, or simply get more protein without cooking. But a major new investigation by Consumer Reports has…
-
The Parasite Affecting 1 in 3 People – And How It Can Threaten Your Vision
Most people have never heard of Toxoplasma gondii, yet this microscopic parasite has quietly infected an enormous portion of the global population. Depending on where you live, anywhere from 25 percent to more than 60 percent of people carry it. In some regions, the infection rate is even higher. Many people never feel sick, never…